Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dalpiciclib plus Abiraterone and Prednisone in mHSPC
NCT06099990Phase 1Not yet recruiting
- Sponsor
- Hengrui
- Start
- Oct 2023
- Primary completion
- Dec 2028
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, double-blind trial in prostate cancer (PCa) comparing Dalpiciclib + AA-P with Placebo + AA-P (2 arms). Primary endpoint: Adverse event (AE) incidence. Planned start Oct 2023; status: not yet recruiting.
02
Drugs
dalpiciclib
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT06099990.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06099990.